Delivered
Michigan
Destination state
Carrier-confirmed deliveryThe supplied tracking record shows this shipment as delivered.
Recipient details withheld
Medical Review Statement
Educational content updated October 1, 2026 using the sources listed below. Medically reviewed by Dr. Fremlin Dekyi, MD. Reviewed: October 1, 2026. This content does not replace individualized medical advice.
Quick Answer
The main difference
Wegovy contains semaglutide; Zepbound contains tirzepatide. Both are prescription options for chronic weight management, but their receptor activity, labeled uses and formulations differ. Tirzepatide produced greater average weight loss in SURMOUNT-5 at the specific injection doses studied.
Treatment comparison
| Dimension | Semaglutide / Wegovy | Tirzepatide / Zepbound |
|---|---|---|
| Active ingredient / action | Semaglutide; GLP-1 receptor agonist | Tirzepatide; GIP and GLP-1 receptor agonist |
| Weight-management brand | Wegovy | Zepbound |
| Diabetes brand | Ozempic (not approved for weight management) | Mounjaro (not the weight-management brand) |
| Adult weight-management eligibility | Obesity, or overweight with a weight-related condition | Obesity, or overweight with a weight-related condition |
| Other brand-specific indications | Wegovy: cardiovascular risk reduction in eligible adults; injection also has an accelerated-approval MASH indication | Zepbound: moderate-to-severe obstructive sleep apnea in adults with obesity |
| Weekly injection initiation | 0.25 mg weekly for 4 weeks, followed by gradual escalation | 2.5 mg weekly for 4 weeks; increase to 5 mg, then 2.5 mg steps after at least 4 weeks at each dose |
| Maintenance / formulations | Usual injection maintenance 2.4 mg; other options depend on indication and tolerance. Current label includes 7.2 mg HD for eligible adults and daily tablets (25 mg maintenance) | Weight management: 5, 10 or 15 mg weekly; sleep apnea: 10 or 15 mg. 2.5 mg is an initiation dose |
| Common tolerability issues | Nausea, vomiting, diarrhea, constipation and abdominal discomfort | Nausea, vomiting, diarrhea, constipation and abdominal discomfort |
| Distinct counseling | Semaglutide: discuss diabetic retinopathy history; stop at least 2 months before planned pregnancy for weight management | Tirzepatide: oral contraceptive precautions for 4 weeks after starting and after every dose increase |
| Cost / coverage | Depends on brand, formulation, indication, insurance and pharmacy | Depends on brand, presentation, indication, insurance and pharmacy |
Head-to-head weight-loss evidence
The 2025 SURMOUNT-5 trial directly compared these injection regimens. Results should not be extrapolated to every dose, formulation, compounded product or person with diabetes.
| Trial feature | SURMOUNT-5 |
|---|---|
| Population | Adults with obesity without type 2 diabetes |
| Design | Randomized, open-label, 72 weeks; maximum tolerated weekly injection doses |
| Tirzepatide | 10 or 15 mg; mean weight change −20.2% |
| Semaglutide | 1.7 or 2.4 mg; mean weight change −13.7% |
| Interpretation | Study averages, not guaranteed results; does not compare oral semaglutide or Wegovy HD 7.2 mg |
Side effects and safety considerations
Both carry a boxed warning about thyroid C-cell tumors observed in rodents; the human relevance is unknown. They are contraindicated with a personal or family history of medullary thyroid carcinoma, MEN 2 or a serious allergy to the respective medicine. Severe gastroparesis, pregnancy plans, pancreatitis and gallbladder history require discussion.
Both can cause dehydration-related kidney injury and low blood sugar when used with insulin or sulfonylureas. Tell your anesthesia team before procedures because delayed stomach emptying may increase aspiration risk.
Seek urgent medical care for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, fainting, or very little urine. Trouble breathing or swelling of the face or throat is an emergency. Severe bloating with vomiting or inability to pass stool or gas also needs urgent assessment.
How a clinician chooses between treatments
A clinician weighs your treatment goal, diabetes status, cardiovascular history, sleep apnea, kidney health, gastrointestinal tolerance, other medicines, pregnancy plans and access. A trial average cannot predict your individual response. Do not combine these medicines or switch doses yourself.
Ask your insurer about the exact brand and indication: formulary status, prior authorization, documented BMI and conditions, step therapy and renewal requirements can differ. Compare the total ongoing cost, including visits, labs, pharmacy charges and supplies; introductory prices and savings offers may change.
What to discuss with your clinician
- Your diagnosis, treatment goals and medical history.
- The exact product, dose, safety precautions and ongoing cost.
- Your follow-up plan and symptoms that need prompt assessment.
Best next step
Use consultation to turn search intent into a real treatment decision
Patients usually get more value from medical review, fit assessment, and follow-up planning than from choosing a medication based only on headlines or social posts.
Frequently asked questions
In SURMOUNT-5, tirzepatide averaged 20.2% weight reduction versus 13.7% with semaglutide over 72 weeks at the studied doses. Individual results vary, and newer semaglutide formulations were not compared.
Your prescriber must plan the switch and starting dose using your symptoms, previous dose and time since treatment. Milligrams are not equivalent between medicines.
There is no universal answer. Request an estimate for your exact prescription after your plan's deductible, authorization requirements and pharmacy benefits.
